Total Results: 489
Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
In Blow To Pharma, Maryland Law Punishing Price Gouging Allowed To Go Into Effect
A group representing pharmaceutical makers asked a judge to stop the law from going into effect, but U.S. District Judge Marvin Garbis found that “an erroneous grant of a preliminary injunction would cause substantial harm by permitting the sale of essential drugs to Maryland residents at unconscionable prices.”
Nation Could Be Hit With Drug Shortages After Hurricane Slams Puerto Rico
The agency is closely tracking 40 high-priority drugs that are deemed essential and could run short nationally following potential damage to the island’s dozens of drugmaking plants. Meanwhile, the hurricane killed most mosquitoes that carry the Zika virus.
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Pocos se benefician con las nuevas drogas anti colesterol por el gran gasto de bolsillo
Una nueva generación de drogas podría ayudar a millones a bajar los niveles de colesterol malo. Pero el proceso para lograr una receta y el alto costo para el paciente están limitando su uso.
Massachusetts Asks To Be Able To Limit Which Drugs Medicaid Has To Cover
The somewhat controversial move would shift the state toward what is known in the insurance world as a closed formulary. This allows an insurer to provide coverage for only certain drugs that are made available on favorable terms. Meanwhile, Rep. Elijah Cummings (D-Md.) takes to Twitter to demand President Donald Trump take action on high prices, and a new study finds a promising drug’s costs is limiting the number of people who can take it.
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
‘Given The Scope Of This Crisis,’ PhRMA CEO Backs Guidelines Limiting Opioid Prescriptions
The move follows efforts by pharmacy benefit managers to restrict the supply of opioids to first-time users. The decision is creating some backlash for patients with chronic pain who are worried they can no longer get the treatment they and their doctors feel they need.
Perspectives: Keep An Eye On California’s Bills To Curb High Drug Prices
Read recent commentaries about drug-cost issues.
Orphan Drug Costs A Headache For Insurers, But Many Aren’t Touching Politically Sensitive Topic
News outlets report on stories related to pharmaceutical pricing.
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Viewpoints: Examining The Link Between Opioids And Medicaid; Putting The Squeeze On ACA Navigators
A selection of opinions on health care from around the country, including a range of thoughts on the Medicaid program and prescription drug costs.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Drug’s $475K Cost Highlights Pricing Problems With Unique, Breakthrough Therapies
“We need a new payment model,” Steve Miller, chief medical officer at Express Scripts Holding Co., said while criticizing Novartis’ new drug.
Viewpoints: The Promise And Price Tag Of A New Cancer Drug; Medicaid In Indian Country
A selection of opinions on health care from around the country.
Pfizer-J&J Legal Brawl Could Set Precedent For Competition In Biosimilar Landscape
If Pfizer is successful, it could discourage brand name companies from using deals with insurers to limit competition in the emerging biosimilar market. If Pfizer loses, the case could highlight a strategy those companies could continue to use to deter competition.
Perspectives: Drugmakers Love To Hide Behind R&D Costs. Are They Justified?
Read recent commentaries about drug-cost issues.
This Caustic Crusader With A Knack For Making Enemies Has Especially Harsh Words For Pharma
News outlets report on stories related to pharmaceutical pricing.
In Blow To GSK, Judge Upholds Verdict In Case Over Paxil’s Link To Suicide
The federal court jury decided GlaxoSmithKline failed to properly warn about the risk of its medicine.
